Comparison of Outcomes of Allogeneic Transplantation for XXXX with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation.

@entity1 @entity1778 @entity348 @entity1860
UNASSIGNED: Cyclophosphamide (Cy) in combination with busulfan (Bu) or @entity348 ( @entity348 ) is the most commonly used myeloablative conditioning regimen in @entity1 with @entity1860 ( @entity1860 ). We used data from the Center for International Bone Marrow Transplantation Research to compare outcomes in adults who underwent hematopoietic cell transplantation for @entity1860 in first chronic phase after myeloablative conditioning with Cy in combination with @entity348 , oral Bu, or intravenous (i.v.) Bu. Four hundred thirty-eight adults received human leukocyte antigen (HLA)-matched sibling grafts and 235 received well-matched grafts from unrelated donors (URD) from 2000 through 2006. Important differences existed between the groups in distribution of donor relation, exposure to tyrosine kinase inhibitors, and year of transplantation. In multivariate analysis, relapse occurred less frequently among @entity1 receiving i.v. Bu compared with @entity348 (relative risk [RR], .36; P  =  .022) or oral Bu (RR, .39; P  =  .028), but nonrelapse mortality and survival were similar. A significant interaction was detected between donor relation and the main effect in @entity1778 ( @entity1778 ). Among recipients of HLA-identical sibling grafts, but not URD grafts, @entity1778 was better in @entity1 receiving i.v. Bu (RR, .53; P  =  .025) or oral Bu (RR, .64; P  =  .017) compared with @entity348 . In @entity1860 in first chronic phase, Cy in combination with i.v. Bu was associated with less relapse than @entity348 or oral Bu. @entity1778 was better after i.v. or oral Bu compared with @entity348 .
